Contact
      Please use this form to send email to PR contact of this press release:
      
      Biomed Industries, Inc.  to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025
    
      TO:
      
      Michael Willis
      
      Biomed Industries, Inc.
      
      +1 800-824-5135